相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
V Subbiah et al.
ANNALS OF ONCOLOGY (2022)
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
Hsiang-Fong Kao et al.
CLINICAL CANCER RESEARCH (2022)
Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2022)
Encorafenib plus cetuximab treatment in BRAF V600-Emutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
Emilie Hafliger et al.
EUROPEAN JOURNAL OF CANCER (2022)
Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab
Daniel J. Glazar et al.
ORAL ONCOLOGY (2022)
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Andrea Cercek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response
Sean P. Korpela et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma
Mei-Kim Ang et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2021)
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
Christine H. Chung et al.
CANCERS (2021)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco et al.
LANCET ONCOLOGY (2021)
Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).
Julie E. Bauman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
Hirofumi Shibata et al.
FRONTIERS IN ONCOLOGY (2021)
TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
G. R. Oxnard et al.
ANNALS OF ONCOLOGY (2020)
A randomized, phase 1, placebo-controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes
Saroj K. Basak et al.
CANCER (2020)
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer
Eri Sugiyama et al.
SCIENCE IMMUNOLOGY (2020)
A review of cancer immunotherapy: from the past, to the present, to the future
K. Esfahani et al.
CURRENT ONCOLOGY (2020)
Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma
Won Jong Jin et al.
FRONTIERS IN IMMUNOLOGY (2020)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.
Assuntina Gesualda Sacco et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw et al.
CANCER RESEARCH (2019)
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
Anna W. Chalmers et al.
TARGETED ONCOLOGY (2019)
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Elham Alsahafi et al.
CELL DEATH & DISEASE (2019)
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
Marzia Del Re et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression
Sanjay Chandrasekaran et al.
MOLECULAR CANCER RESEARCH (2019)
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
Rintu Thomas et al.
FRONTIERS IN ONCOLOGY (2019)
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer
Satomi Watanabe et al.
CANCER SCIENCE (2019)
A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
Sadamoto Zenda et al.
FRONTIERS IN ONCOLOGY (2019)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer
Wenbo Ma et al.
PLOS ONE (2018)
PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients
Fernando Concha-Benavente et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6)
Jolie Ringash et al.
EUROPEAN JOURNAL OF CANCER (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Head and neck cancer: improving outcomes with a multidisciplinary approach
Cristiana Lo Nigro et al.
CANCER MANAGEMENT AND RESEARCH (2017)
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma A Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer
Fernando Concha-Benavente et al.
CANCER RESEARCH (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Danny Rischin et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialaEuro
P. M. Clement et al.
ANNALS OF ONCOLOGY (2016)
Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2016)
Phase Ib Study of Duligotuzumab (MEHD7945A) Plus Cisplatin/5-Fluorouracil or Carboplatin/Paclitaxel for First-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Antonio Jimeno et al.
CANCER (2016)
B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients
Yu Yao et al.
CLINICAL CANCER RESEARCH (2016)
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
Jessica L. Geiger et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
Ling Dong et al.
ONCOTARGET (2016)
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Elliott J. Brea et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Jerome Fayette et al.
FRONTIERS IN ONCOLOGY (2016)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Floriana Morgillo et al.
ESMO OPEN (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
E. Massarelli et al.
ANNALS OF ONCOLOGY (2015)
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
J. Guigay et al.
ANNALS OF ONCOLOGY (2015)
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Kailong Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
CXCR3 ligands in disease and therapy
Katrien Van Raemdonck et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Emerging drugs for head and neck cancer
Yihui Wen et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Kevin Harrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial
Jordi Giralt et al.
LANCET ONCOLOGY (2015)
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
Ricard Mesia et al.
LANCET ONCOLOGY (2015)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels et al.
LANCET ONCOLOGY (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma
Arun Khattri et al.
ORAL ONCOLOGY (2015)
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
Jill Gilbert et al.
ORAL ONCOLOGY (2015)
EGFR and NF-κB: partners in cancer
Kateryna Shostak et al.
TRENDS IN MOLECULAR MEDICINE (2015)
The insulin and IGF1 receptor kinase domains are functional dimers in the activated state
M. Zulema Cabail et al.
NATURE COMMUNICATIONS (2015)
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)
V. Gruenwald et al.
ANNALS OF ONCOLOGY (2015)
HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Netanya I. Pollock et al.
CLINICAL CANCER RESEARCH (2015)
Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Tanguy Y. Seiwert et al.
CLINICAL CANCER RESEARCH (2015)
Emerging biomarkers in head and neck cancer in the era of genomics
Hyunseok Kang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
T. Y. Seiwert et al.
ANNALS OF ONCOLOGY (2014)
Phase 1 and Pharmacokinetic Study of Everolimus in Combination With Cetuximab and Carboplatin for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Nabil F. Saba et al.
CANCER (2014)
Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer
Andrew Sewell et al.
CLINICAL CANCER RESEARCH (2014)
Evaluation of the EGFR-Inhibitor Zalutumumab Given With Primary Curative (Chemo)radiation Therapy to Patients With Squamous Cell Carcinoma of the Head and Neck: Results of the DAHANCA 19 Randomized Phase 3 Trial Definitive Management of Head-and-Neck Squamous Cell Carcinoma
J. G. Eriksen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors
Barbara Seliger
JOURNAL OF IMMUNOTOXICOLOGY (2014)
Transphosphorylation of EGFR at Y845 plays an important role in its autophosphorylation and kinase activity
Hui Song et al.
ONCOLOGY REPORTS (2014)
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A. R. Abdul Razak et al.
ANNALS OF ONCOLOGY (2013)
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
Matthew G. Fury et al.
CANCER (2013)
Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
Jianghong Wu et al.
CURRENT CANCER DRUG TARGETS (2013)
Promising New Molecular Targeted Therapies in Head and Neck Cancer
Kelly Dorsey et al.
DRUGS (2013)
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease
Kevin Harrington et al.
EUROPEAN JOURNAL OF CANCER (2013)
A Phase 1 Study of Everolimus plus Weekly Cisplatin plus Intensity Modulated Radiation Therapy in Head-and-Neck Cancer
Matthew G. Fury et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
Athanassios Argiris et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
Renato G. Martins et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor
M. Iida et al.
ONCOGENE (2013)
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
Julie E. Bauman et al.
ORAL ONCOLOGY (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
EGFR-mediated tumor immunoescape The imbalance between phosphorylated STAT1 and phosphorylated STAT3
Fernando Concha-Benavente et al.
ONCOIMMUNOLOGY (2013)
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
R. Hitt et al.
ANNALS OF ONCOLOGY (2012)
The mTOR Signalling Pathway in Human Cancer
Helena Populo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the PI3K/mTOR pathway
Zhuo Li et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Vemurafenib: the first drug approved for BRAF-mutant cancer
Gideon Bollag et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
EGFR inhibitors, MHC expression and immune responses Can EGFR inhibitors be used as immune response modifiers?
Brian P. Pollack
ONCOIMMUNOLOGY (2012)
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial
M. R. Posner et al.
ANNALS OF ONCOLOGY (2011)
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
J. B. Vermorken et al.
BRITISH JOURNAL OF CANCER (2011)
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
J. M. del Campo et al.
BRITISH JOURNAL OF CANCER (2011)
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes
Michael S. Leibowitz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
Brian P. Pollack et al.
CLINICAL CANCER RESEARCH (2011)
Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment
Ingeborg Tinhofer et al.
CLINICAL CANCER RESEARCH (2011)
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels et al.
LANCET ONCOLOGY (2011)
The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Nicole G. Chau et al.
HEAD & NECK ONCOLOGY (2011)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
Erika Martinelli et al.
CLINICAL CANCER RESEARCH (2010)
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Shomit Sengupta et al.
MOLECULAR CELL (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation
S. E. Wheeler et al.
ONCOGENE (2010)
Regulation Mechanisms and Signaling Pathways of Autophagy
Congcong He et al.
ANNUAL REVIEW OF GENETICS (2009)
Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment
Sara I. Pai et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Melarkode S. Ramakrishnan et al.
MABS (2009)
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
Jan. B. Vermorken et al.
CANCER (2008)
Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States
Anil K. Chaturvedi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
Carole Fakhry et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage
David J. Chen et al.
CLINICAL CANCER RESEARCH (2007)
The epidermal growth factor receptor: from development to tumorigenesis
Maria Sibilia et al.
DIFFERENTIATION (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group study
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
TheEGF receptor family: spearheading a merger of signaling and therapeutics
Erez M. Bublil et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer
A. Jebreel et al.
JOURNAL OF LARYNGOLOGY AND OTOLOGY (2007)
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
J. J. Cruz et al.
ANNALS OF ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels
Chunxiao Zhou et al.
GYNECOLOGIC ONCOLOGY (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro
M Abe et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
DC Fingar et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
JB Brugarolas et al.
CANCER CELL (2003)
The immuno suppress ant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation
T Peng et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
